Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

730 Articles

Trey Thoelcke | Apr 7, 2014 at 8:25 AM EDT

Credit Suisse Says Grit Your Teeth and Buy Biotech

In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016…

Jon C. Ogg | Apr 4, 2014 at 8:20 AM EDT

Stifel Says Strong Earnings Will Reignite Biotech Rally

ThinkstockWhen the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering…

Jon C. Ogg | Apr 2, 2014 at 3:37 PM EDT

Biotech Giants Now Priced Like Old World Drug Stocks

Jon OggMost investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position…

Jon C. Ogg | Apr 2, 2014 at 8:20 AM EDT

Large Cap Biotechs Trading With Only Big Pharma P/E Ratios

In a new report from RBC, its analysts say that biotech stocks trading at some of the lowest forward multiples…

Jon C. Ogg | Mar 27, 2014 at 8:55 AM EDT

Morgan Stanley Starts Mixed Coverage on Top Biotech Stocks

courtesy of Morgan StanleyLike many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley…

Trey Thoelcke | Mar 26, 2014 at 7:25 AM EDT

Short Sellers Find Renewed Interest in Biotech Stocks

After retreating from many leading biotech and emerging pharmaceutical stocks in the previous two periods, short sellers returned in early…

Trey Thoelcke | Mar 24, 2014 at 9:55 AM EDT

Top Biotechnology Stocks On Sale Again

For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from…

Trey Thoelcke | Mar 12, 2014 at 7:10 AM EDT

Short Sellers Retreat From Biotech Stocks Again

Biotech and emerging pharmaceutical stocks continue to be hot, but short sellers shied away from many of them in late…

Trey Thoelcke | Mar 11, 2014 at 8:45 AM EDT

Catalysts That Could Push Top Biotech Stocks Even Higher

Many bears on Wall Street say that biotech stocks are overvalued, but many trade in line with historical valuations. In…

Trey Thoelcke | Mar 4, 2014 at 8:50 AM EST

Merrill Lynch’s Top Health Care Stocks to Buy Now

Merrill Lynch likes the health care sector and has made no secret that they think that it can continue to…

Trey Thoelcke | Feb 27, 2014 at 7:00 AM EST

Short Sellers Return to Biotech Stocks

After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical…

Trey Thoelcke | Feb 26, 2014 at 8:25 AM EST

Six New Stocks to Buy in the Piper Jaffray Model Portfolio

Most Wall Street firms run model portfolios for their institutional and retail clients. Here are stocks that recently were added…

Trey Thoelcke | Feb 24, 2014 at 8:20 AM EST

Deutsche Bank Unveils Its “What to Buy Now?” List

In a new research report, the analysts at Deutsche Bank unveil their "what to buy now ?" list for large…

Jon C. Ogg | Feb 13, 2014 at 10:40 AM EST

Top Pharma and Biotech Stocks to Buy From Key Investor Conference

With top biotechnology and health care companies from around the world attending the Leerink Global Healthcare, it is a good…

Trey Thoelcke | Feb 12, 2014 at 6:50 AM EST

Short Sellers Shy Away From Biotechs

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers…

1 … 37 38 39 40 41 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Credit Suisse Says Grit Your Teeth and Buy Biotech

Stifel Says Strong Earnings Will Reignite Biotech Rally

Biotech Giants Now Priced Like Old World Drug Stocks

Large Cap Biotechs Trading With Only Big Pharma P/E Ratios

Morgan Stanley Starts Mixed Coverage on Top Biotech Stocks

Short Sellers Find Renewed Interest in Biotech Stocks

Top Biotechnology Stocks On Sale Again

Short Sellers Retreat From Biotech Stocks Again

Catalysts That Could Push Top Biotech Stocks Even Higher

Merrill Lynch’s Top Health Care Stocks to Buy Now

Short Sellers Return to Biotech Stocks

Six New Stocks to Buy in the Piper Jaffray Model Portfolio

Deutsche Bank Unveils Its “What to Buy Now?” List

Top Pharma and Biotech Stocks to Buy From Key Investor Conference

Short Sellers Shy Away From Biotechs

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Gilead Sciences : GILD

All Gilead Sciences Articles

Credit Suisse Says Grit Your Teeth and Buy Biotech

Stifel Says Strong Earnings Will Reignite Biotech Rally

Biotech Giants Now Priced Like Old World Drug Stocks

Large Cap Biotechs Trading With Only Big Pharma P/E Ratios

Morgan Stanley Starts Mixed Coverage on Top Biotech Stocks

Short Sellers Find Renewed Interest in Biotech Stocks

Top Biotechnology Stocks On Sale Again

Short Sellers Retreat From Biotech Stocks Again

Catalysts That Could Push Top Biotech Stocks Even Higher

Merrill Lynch’s Top Health Care Stocks to Buy Now

Short Sellers Return to Biotech Stocks

Six New Stocks to Buy in the Piper Jaffray Model Portfolio

Deutsche Bank Unveils Its “What to Buy Now?” List

Top Pharma and Biotech Stocks to Buy From Key Investor Conference

Short Sellers Shy Away From Biotechs

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

Featured Reads

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It